Literature DB >> 34730257

Single-cell profiling of T lymphocytes in deficiency of adenosine deaminase 2.

Zhijie Wu1, Shouguo Gao1, Naoki Watanabe1, Sai Batchu1, Sachiko Kajigaya1, Carrie Diamond1, Lemlem Alemu1, Diego Quinones Raffo1, Xingmin Feng1, Patrycja Hoffmann2, Deborah Stone2, Amanda Ombrello2, Neal S Young1.   

Abstract

Deficiency of adenosine deaminase 2 (DADA2) is a monogenic vasculitis syndrome caused by autosomal-recessive loss-of-function mutations in the ADA2 gene (previously known as CECR1). Vasculitis, vasculopathy, and inflammation are dominant clinical features of this disease; the spectrum of manifestations includes immunodeficiency and lymphoproliferation as well as hematologic manifestations. ADA2 is primarily secreted by stimulated monocytes and macrophages. Aberrant monocyte differentiation to macrophages and neutrophils are important in the pathogenesis of DADA2, but little is known about T lymphocytes in this disease. We performed combined single-cell RNA sequencing and single-cell TCR sequencing in order to profile T cell repertoires in 10 patients with DADA2. Although there were no significant alterations of T cell subsets, we observed activation of both CD8+ and CD4+ T cells. There was no clonal expansion of T cells: most TCRs were expressed at basal levels in patients and healthy donors. TCR usage was private to individual patients and not disease specific, indicating as unlikely a common pathogenic background or predisposition to a common pathogen. We recognized activation of IFN pathways as a signature of T cells and STAT1 as a hub gene in the gene network of T cell activation and cytotoxicity. Overall, T cells in DADA2 patients showed distinct cell-cell interactions with monocytes, as compared with healthy donors, and many of these ligand-receptor interactions likely drove up-regulation of STAT1 in both T cells and other immune cells in patients. Our analysis reveals previously undercharacterized cell characteristics in DADA2. Published 2021. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  T lymphocytes; deficiency of adenosine deaminase 2; single-cell RNA sequencing

Mesh:

Substances:

Year:  2021        PMID: 34730257     DOI: 10.1002/JLB.5A0621-314R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  5 in total

1.  Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis.

Authors:  Zhao-Wei Gao; Lan Yang; Chong Liu; Xi Wang; Wen-Tao Guo; Hui-Zhong Zhang; Ke Dong
Journal:  Front Immunol       Date:  2022-05-18       Impact factor: 8.786

2.  Lentiviral Mediated ADA2 Gene Transfer Corrects the Defects Associated With Deficiency of Adenosine Deaminase Type 2.

Authors:  Ying Hong; Marina Casimir; Benjamin C Houghton; Fang Zhang; Barbara Jensen; Ebun Omoyinmi; Robert Torrance; Charalampia Papadopoulou; Michelle Cummins; Marion Roderick; Adrian J Thrasher; Paul A Brogan; Despina Eleftheriou
Journal:  Front Immunol       Date:  2022-04-22       Impact factor: 8.786

Review 3.  Adenosine Deaminase 2 Deficiency (DADA2): A Crosstalk Between Innate and Adaptive Immunity.

Authors:  Sara Signa; Arinna Bertoni; Federica Penco; Roberta Caorsi; Alessia Cafaro; Giuliana Cangemi; Stefano Volpi; Marco Gattorno; Francesca Schena
Journal:  Front Immunol       Date:  2022-07-11       Impact factor: 8.786

Review 4.  Research progress on application of single-cell TCR/BCR sequencing technology to the tumor immune microenvironment, autoimmune diseases, and infectious diseases.

Authors:  Jinhua He; Jian Shen; Wenfeng Luo; Zeping Han; Fangmei Xie; Ting Pang; Liyin Liao; Zhonghui Guo; Jianhao Li; Yuguang Li; Hanwei Chen
Journal:  Front Immunol       Date:  2022-08-18       Impact factor: 8.786

5.  CellCallEXT: Analysis of Ligand-Receptor and Transcription Factor Activities in Cell-Cell Communication of Tumor Immune Microenvironment.

Authors:  Shouguo Gao; Xingmin Feng; Zhijie Wu; Sachiko Kajigaya; Neal S Young
Journal:  Cancers (Basel)       Date:  2022-10-10       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.